PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Koas is attempting to exit capital impairment through rights issues and convertible bond conversions while pursuing diversification into biotech, even as its core office furniture revenue has declined for several straight years.
2025 consolidated revenue was KRW 62.2 billion, sharply down from KRW 97.9 billion in 2022, marking a fourth straight year of operating losses.
Operating profit briefly turned positive at KRW 1.9 billion in Q1 2026 before reverting to a loss of KRW 0.77 billion in Q2 2026.
The 2025 net loss attributable to owners widened to KRW 31.3 billion from KRW 8.9 billion a year earlier, with a single quarter (Q3) accounting for KRW 21.4 billion of that loss.
The company has been pursuing a stake acquisition in drug developer Novelty Nobility, extending its business scope from office furniture into bio and healthcare.
The company has repeatedly faced listing-related issues, including administrative issue designation for falling below market cap thresholds and a prior unfaithful disclosure designation.
Koas is an office furniture specialist founded in 1984 and listed on the KOSPI in 2005 under the former name Korea OA.
The company produces office furniture under the Millennium and U-Plex lines as well as student desks and chairs, positioning smart-office-concept products incorporating IT technology as its core offering.
It operates a domestic distribution network of roughly 170 dealers alongside export channels covering about 30 countries.
The competitive landscape mixes large brands such as Fursys, Hanssem, Hyundai Livart, Ace Bed, and Zinus with smaller furniture makers, and a recent brand reputation ranking placing Ace Bed, Hanssem, Fursys, Zinus, and Hyundai Livart at the top underscores Koas's relatively weaker brand recognition.
Following a change in controlling shareholder, the company pursued entry into biotech by acquiring a stake in drug developer Novelty Nobility, announcing a plan involving roughly KRW 50 billion in third-party rights issues and convertible bond subscriptions.
The transaction proved turbulent, however, as a contract termination notice from Novelty Nobility in September 2025 derailed the initial capital payment, and subsequent reports indicated a revised agreement transferring a controlling stake to Koas.
Around the same period, the company also made a large purchase of shares in the delisting-bound Ewha Group companies (Ewha Electronics, Etron, and EID), becoming Ewha Electronics' largest shareholder, a process that led to an unfaithful disclosure designation over delayed and inaccurate filings.
Since the ownership change, Roh Byung-gu, formerly head of Solux, has served as co-CEO, jointly overseeing both the core furniture business and the new ventures.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩10.9B | -₩2.2B | −20.3% |
| 2025Q3 | ₩12B | -₩2.5B | −21.0% |
| 2025Q4 | ₩19B | -₩1B | −5.2% |
| 2026Q1 | ₩21.4B | ₩1.9B | 8.9% |
| 2026Q2 | ₩15.8B | -₩800M | −4.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩97.9B | -₩700M | -₩1.9B | −0.7% | −11.0% | 326.7% |
| 2023 | ₩73.7B | -₩3B | -₩6.9B | −4.1% | −67.6% | 549.4% |
| 2024 | ₩78B | -₩7.2B | -₩8.9B | −9.3% | −447.2% | 3300.6% |
| 2025 | ₩62.2B | -₩5.7B | -₩31.3B | −9.1% | −90.7% | 134.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue moved from KRW 97.9 billion in 2022 to KRW 73.7 billion in 2023, KRW 78.0 billion in 2024, and KRW 62.2 billion in 2025, showing an overall contracting trend despite some fluctuation.
Operating losses widened from KRW 0.7 billion in 2022 to KRW 3.0 billion in 2023 and KRW 7.2 billion in 2024 before narrowing somewhat to KRW 5.7 billion in 2025, yet the company remained in the red for a fourth consecutive year.
Net losses attributable to owners rose gradually from KRW 1.9 billion in 2022 to KRW 6.9 billion in 2023 and KRW 8.9 billion in 2024, then jumped sharply to KRW 31.3 billion in 2025, a result driven almost entirely by a single quarter—Q3 2025—which alone accounted for KRW 21.4 billion of net losses.
That period coincided with the contract termination notice on the Novelty Nobility acquisition and the unfaithful disclosure controversy tied to the Ewha Group share purchases, suggesting one-off factors linked to the new ventures weighed heavily on results.
Revenue recovered to KRW 19.0 billion in Q4 2025 with the net loss narrowing to KRW 0.8 billion, and Q1 2026 revenue reached KRW 21.4 billion with operating profit turning positive at KRW 1.9 billion.
However, Q2 2026 revenue fell back to KRW 15.8 billion, operating profit reverted to a loss of KRW 0.8 billion, and the net loss widened to KRW 3.1 billion, indicating the recovery has yet to prove durable.
On the balance sheet, owners' equity, which had shrunk to KRW 2.0 billion at end-2024 and approached complete capital impairment, rose to KRW 34.5 billion by end-2025, with the debt ratio falling from over 3,300% to 134.5%, an improvement on paper.
Still, operating cash flow remained negative at KRW 5.4 billion in 2025, and aside from 2023 (positive KRW 0.8 billion), three of the last four fiscal years posted negative operating cash flow.
The domestic office furniture market is generally viewed as mature with stalled growth, and rising raw material costs combined with a global economic slowdown have repeatedly driven furniture makers to consider diversification.
In the office furniture segment where Koas operates, large integrated furniture makers such as Fursys, Hanssem, and Hyundai Livart compete alongside mattress and overseas-online-focused Zinus and specialty brand Ace Bed, making it difficult for smaller players to build brand power.
A recent brand reputation survey did not place Koas among the top-ranked names, underscoring a gap in consumer recognition versus larger brands.
Against this backdrop, a growing number of manufacturing-based companies have expanded into bio and healthcare, with Orion's acquisition of LigaChem Biosciences frequently cited as a reference case.
Koas's attempt to acquire Novelty Nobility fits this broader pattern of cross-industry diversification, though drug development is classified as a high-risk, high-return industry typically requiring more than a decade and substantial capital.
With the core furniture business's revenue base continuing to shrink, it will likely take time for the new venture to establish itself as a stable revenue source, and the resulting need to fund both the legacy business and the new venture simultaneously is a risk shared with other cross-industry diversification cases in the sector.
The company has stated it is seeking ways to maintain its listing following the Q1 2026 return to operating profit, reaffirming its intent to pursue high-value-added businesses beyond core furniture.
As part of an eco-friendly push, it has also been marketing brand image improvements, including launching the 'RE-Born' furniture line made from wildfire-damaged timber.
On the new venture side, Novelty Nobility has indicated ongoing licensing discussions for its clinical-stage allergy treatment candidate NN2802 and antibody-drug conjugate cancer candidate NN3201, meaning progress on these pipelines could also bear on the outcome of Koas's bio investment.
However, the agreement to transfer a controlling stake in Novelty Nobility went through a termination notice in September 2025 before reportedly being restructured under revised terms, leaving the final completion and timing uncertain.
On the financing side, Koas has continued conducting successive third-party rights issues into 2026 to fund operations, with new share issue prices repeatedly set at a discount to market price.
A substantial volume of previously issued convertible bonds and bonds with warrants remains outstanding for conversion; while conversion into equity would help resolve the capital impairment, it would also entail further dilution from the resulting increase in shares outstanding.
How this financing and ownership structure evolution interacts with the recovery of core operating performance remains a key point to watch.
Koas has posted both operating and net losses in each of the past four fiscal years, making profit-based valuation metrics difficult to apply, so discussion of the stock tends to center on asset-value comparisons instead.
The current share price trades below per-share net asset value, placing it in a discount range relative to book value.
That said, it is worth noting that the capital structure, which came close to complete impairment at end-2024, improved through 2025 primarily via external financing—rights issues and convertible bond conversions—rather than through profit accumulation from operations.
No dividends have been paid in recent years, making dividend-based metrics largely inapplicable. Going forward, valuation discussion is likely to hinge on the pace of recovery in core furniture revenue and margins alongside whether the bio venture, including Novelty Nobility, produces visible results.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Operating profit turned positive at KRW 1.9 billion in Q1 2026, hinting at a possible break from four straight years of annual losses. The company's CEO cited this result while discussing efforts to maintain the listing.
However, since the figure reverted to a loss in Q2, whether the positive trend can be sustained requires further confirmation.
Owners' equity, which had approached complete capital impairment at end-2024, grew to KRW 34.5 billion by end-2025, while the debt ratio fell from over 3,300% to 134.5%. Successive third-party rights issues and conversions of convertible bonds and bonds with warrants appear to have contributed to this improvement.
That said, this stemmed from external financing rather than profit accumulation from operations, a point worth weighing alongside the improvement.
Through the Novelty Nobility stake acquisition, Koas is attempting to gain exposure to an allergy treatment and an antibody-drug conjugate cancer pipeline. These pipelines have reportedly already reached clinical stages, with licensing discussions said to be ongoing.
The new venture could offer a growth option distinct from recovery in the core business, though the deal's history carries persistent uncertainty.
Annual revenue fell sharply from KRW 97.9 billion in 2022 to KRW 62.2 billion in 2025 over four years. Stalled growth in the domestic office furniture market combined with raw material cost pressure has limited room for a rebound in the core business. If core revenue keeps declining before the new venture takes hold, it could weigh on overall performance.
The company went through an unfaithful disclosure designation process over delayed and inaccurate filings related to the Ewha Group share acquisitions and has a history of administrative issue designation for falling below market cap thresholds.
In June 2026 it was also designated an investment caution stock due to short-term price volatility. This track record is seen as a headwind to rebuilding market trust.
Successive third-party rights issues have continued into 2026, and analysis has pointed to a very large volume of potential conversion from previously issued convertible bonds and bonds with warrants relative to total shares outstanding.
Sequential conversions or additional new share issuances could result in repeated dilution for existing shareholders. The recurring practice of setting new share issue prices at a discount to market price is also worth monitoring.
The company has a repeated history of administrative issue designation for falling below market cap thresholds, unfaithful disclosure designation, and investment caution stock designation.
With a financial structure that came close to complete capital impairment not yet fully stabilized, the possibility of additional regulatory action cannot be ruled out. Continued monitoring of compliance with listing maintenance requirements is warranted.
The Novelty Nobility acquisition is reported to have been restructured under revised terms after a contract termination notice in September 2025, meaning final completion is not yet confirmed.
Drug development is a high-risk industry typically requiring long timeframes and substantial capital, and investment outcomes can vary greatly depending on clinical results or licensing success.
There is also a burden of needing to continuously fund the new venture even as the core business's own financial capacity remains limited.
Consolidated operating cash flow was negative KRW 5.4 billion in 2025, with cash outflows occurring in three of the past four fiscal years.
Prior reports have noted that cash holdings have remained relatively thin, contributing to a structure that relies on external financing through successive third-party rights issues and convertible bond issuances.
Continued reliance on this type of financing could result in an accumulation of both financial burden and shareholder dilution.
Check whether Q3 2026 results confirm renewed revenue recovery and a return to operating profit, or whether the company slips back into losses as it did in Q2.
The annual results should be checked to see whether the exit from complete capital impairment is sustained and whether market cap and capital requirements are met to potentially lift the administrative issue designation.
Further confirmation is needed on whether the Novelty Nobility controlling-stake acquisition agreement is finally completed and on progress in licensing discussions for the NN2802 and NN3201 pipelines.
The extent of dilution from remaining convertible bond and bond-with-warrant conversions, as well as any additional third-party rights issues, should be continuously monitored.
Koas is a company whose revenue and profitability have contracted over multiple years within the mature office furniture industry, with the 2025 net loss widening to KRW 31.3 billion, marking a peak in financial strain.
A brief return to operating profit in Q1 2026 was followed by a reversion to losses in Q2, leaving the durability of any recovery unconfirmed.
The capital structure has moved toward exiting complete impairment through successive rights issues and convertible bond conversions, but this has relied on external financing and comes with attendant dilution.
The bio venture through the Novelty Nobility acquisition remains highly uncertain after going through a contract termination and subsequent restructuring, with both completion and timing still fluid.
Also worth considering are the recurring listing-related issues, including administrative issue designation for falling below market cap thresholds, an unfaithful disclosure designation, and an investment caution stock designation.
On balance, Koas sits at a transitional juncture where recovery of its core business, stabilization of its financial structure, and visibility on new-venture results are unfolding simultaneously, making it important to track progress on each front individually through future quarterly results and disclosures.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.